AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Botulinum Toxins: New Formulations

Description

The discussion covers new formulations of botulinum toxins, focusing on upcoming products and trials in the U.S., as well as comparisons to existing treatments. Notable mentions include Lettibo, recently FDA-approved and already popular in Korea, which has shown a 64.7% patient success rate and a favorable safety profile. Innovations like ready-to-use liquid toxins that require no reconstitution are highlighted for their convenience and potential to reduce errors in dosing. Additionally, new unique liquid formulations such as relabotulinum toxin A and Nevo botulinum toxin A are undergoing trials, offering advantages like faster onset and longer shelf life. A novel botulinum neurotoxin type E shows promise with quicker action and shorter duration, potentially appealing to patients wary of longer-lasting effects. Other developments discussed include nanoparticles for sustained release and the prospect of topical botulinum treatments aimed at improving skin quality. The speaker emphasizes the importance of safety, efficacy, and the broader therapeutic applications of these toxins beyond cosmetics.

View more

Conclusions

  • Letibotulinum toxin A has received FDA approval in the US and shows similar efficacy to other leading botulinum toxins already on the market.
  • Relabotulinum toxin A is a new liquid-form toxin that requires no reconstitution and significantly reduces the risk of errors in preparation.
  • Nivobotulinum toxin A, a ready-to-use formulation, is in the final stages of clinical trials and has promising results for cosmetic applications.
  • Botulinum toxin E offers a rapid onset of action and a shorter duration of effects, potentially appealing to patients seeking more control over their treatment outcomes.
  • Future formulations of botulinum toxins will explore non-muscular effects, targeting conditions like acne, rosacea, and skin quality.
  • The development of topical botulinum toxin formulations could revolutionize the way these treatments are administered, enhancing patient comfort and accessibility.
  • Mueller, Prinz, Adelglass, Cox, Gold, Kaufman-Janette et al. Asthet Surg J 2022;Jan 29;sjac019; BoNT/A, botulinum neurotoxin type A.
  • Mueller et al. Asthet Surg J 2022;Jan 29;sjac019 FWS, Facial Wrinkle Scale: 0 (none), I (mild), 2 (moderate), and 3 (severe).
  • Xie, Yang, Liang, et al. Plastic and Recontruct Surg, January 2024.
  • Yoo, Park et al. J Eur Acad of Dermatol, 2021.
  • Cohen, Moradi, Ablon, Joseph, Kaufman-Janette. Clinical Development Program for RelabotulinumtoxinA, a New Ready-to-use Liquid Botulinum Toxin. Poster presentation.
  • Sundberg, Stahl. Poster presentation at Toxins, 2021.
  • Shridharani, S., et al. Treatment of moderate-to-severe glabellar lines with relabotulinumtoxinA, an investigational liquid toxin. Poster presented at Vegas Cosmetic Surgery; 8-11 June, 2022; Las Vegas, NV, USA.
  • Choudhury et al. Toxins, 2021.
  • Boyer et al. Anaytical Chemistry, 2006.
  • Yoelin, Dhawan et al. Plas Recons Surg 2018.
  • Yoelin et al. Plast Recons Surg, 2018.
  • PONS ET AL. J NEURO SCIENCES 2019.
  • Bhoopalam, M, Qiu, Chenhu et al. Plastic and Reconstructive Surgery May 2023. John Hopkins.